{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:40:22Z","timestamp":1787002822618,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Timely BIBW2992"],"award-info":[{"award-number":["Timely BIBW2992"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,2,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Here we present long-term outcomes of first line afatinib in comorbid patients with suspected or confirmed EGFR mutant NSCLC otherwise considered unsuitable for chemotherapy, and the clinical utility of serial ctDNA monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>TIMELY (NCT01415011) was a multicentre, single arm, phase II trial conducted in the UK. Patients aged \u226518 were treated with daily oral afatinib (40\u2009mg) until disease progression or unacceptable toxicity. Blood samples for ctDNA analysis were obtained at baseline and 12-weekly until treatment discontinuation. The primary endpoint was PFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-nine patients were enrolled between March 2013 and August 2015. Median follow-up was 98 months (range 69-101). Median PFS was 7.9 months (95% CI 4.6-10.5). Seven patients (18%) continued afatinib beyond 18 months, 3 beyond 36 months and 2 were still on treatment at last follow-up 101 months post-treatment initiation. Analysis of baseline ctDNA samples identified 8 EGFR mutant cases that were not identified by tissue genotyping and ctDNA clearance was associated with improved PFS and OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Afatinib is a viable treatment option for tissue or ctDNA-detected EGFR mutant NSCLC comorbid patients, with a proportion achieving long-term clinical benefit. Plasma ctDNA testing improved EGFR mutant identification and its clearance predicted improved PFS and OS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-024-02901-6","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T12:49:49Z","timestamp":1733402989000},"page":"245-252","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy"],"prefix":"10.1038","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2087-4963","authenticated-orcid":false,"given":"Sanjay","family":"Popat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Januszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Lewanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Dernedde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Jankowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Mulatero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyaz","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Geldart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilda","family":"Cominos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3732-8491","authenticated-orcid":false,"given":"James","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Roitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yenting","family":"Ngai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5570-5070","authenticated-orcid":false,"given":"Allan","family":"Hackshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"2901_CR1","unstructured":"National Lung Cancer Audit annual report (for the audit period 2018) Version 2. London: Royal College of Physicians; 2021."},{"key":"2901_CR2","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1200\/JCO.2014.58.1736","volume":"33","author":"CK Lee","year":"2015","unstructured":"Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A, Zhou C, et al. Impact of Specific Epidermal Growth Factor Receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis. J Clin Oncol. 2015;33:1958\u201365.","journal-title":"J Clin Oncol"},{"key":"2901_CR3","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1200\/JCO.2008.18.7658","volume":"27","author":"A Inoue","year":"2009","unstructured":"Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009;27:1394\u20131400.","journal-title":"J Clin Oncol"},{"key":"2901_CR4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10147-021-02043-2","volume":"27","author":"Y Tsubata","year":"2022","unstructured":"Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M, et al. Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). Int J Clin Oncol. 2022;27:112\u201320.","journal-title":"Int J Clin Oncol"},{"key":"2901_CR5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s10637-021-01195-2","volume":"40","author":"S Igawa","year":"2022","unstructured":"Igawa S, Fukui T, Kasajima M, Ono T, Ozawa T, Kakegawa M, et al. First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study. Invest N. Drugs. 2022;40:430\u20137.","journal-title":"Invest N. Drugs"},{"key":"2901_CR6","doi-asserted-by":"publisher","first-page":"8695","DOI":"10.2147\/CMAR.S339891","volume":"13","author":"S Igawa","year":"2021","unstructured":"Igawa S, Kasajima M, Ono T, Ozawa T, Kakegawa M, Kusuhara S, et al. A prospective observational study of osimertinib for chemo-naive elderly patients with EGFR mutation-positive non-small cell lung cancer. Cancer Manag Res. 2021;13:8695\u2013705.","journal-title":"Cancer Manag Res"},{"key":"2901_CR7","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist LV, Yang JC, Yamamoto N, O\u2019Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327\u201334.","journal-title":"J Clin Oncol"},{"key":"2901_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","volume":"15","author":"YL Wu","year":"2014","unstructured":"Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213\u201322.","journal-title":"Lancet Oncol"},{"key":"2901_CR9","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","volume":"16","author":"JC Yang","year":"2015","unstructured":"Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16:830\u20138.","journal-title":"Lancet Oncol"},{"key":"2901_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.lungcan.2018.10.014","volume":"126","author":"H Imai","year":"2018","unstructured":"Imai H, Kaira K, Suzuki K, Anzai M, Tsuda T, Ishizuka T, et al. A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. Lung Cancer. 2018;126:41\u201347.","journal-title":"Lung Cancer"},{"key":"2901_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07861-1","volume":"21","author":"Y Minegishi","year":"2021","unstructured":"Minegishi Y, Yamaguchi O, Sugawara S, Kuyama S, Watanabe S, Usui K, et al. A phase II study of first-line afatinib for patients aged >\/=75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027. BMC Cancer. 2021;21:208.","journal-title":"BMC Cancer"},{"key":"2901_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.lungcan.2020.12.011","volume":"152","author":"F de Marinis","year":"2021","unstructured":"de Marinis F, Laktionov KK, Poltoratskiy A, Egorova I, Hochmair M, Passaro A, et al. Afatinib in EGFR TKI-naive patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study. Lung Cancer. 2021;152:127\u201334.","journal-title":"Lung Cancer"},{"key":"2901_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6107-1","volume":"19","author":"GF Ho","year":"2019","unstructured":"Ho GF, Chai CS, Alip A, Wahid MIA, Abdullah MM, Foo YC, et al. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. BMC Cancer. 2019;19:896.","journal-title":"BMC Cancer"},{"key":"2901_CR14","doi-asserted-by":"publisher","first-page":"23749","DOI":"10.18632\/oncotarget.25255","volume":"9","author":"SK Liang","year":"2018","unstructured":"Liang SK, Lee MR, Liao WY, Ho CC, Ko JC, Shih JY. Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study. Oncotarget. 2018;9:23749\u201360.","journal-title":"Oncotarget"},{"key":"2901_CR15","volume":"2","author":"JB Adizie","year":"2021","unstructured":"Adizie JB, Tweedie J, Khakwani A, Peach E, Hubbard R, Wood N, et al. Biomarker testing for people with advanced lung cancer in England. JTO Clin Res Rep. 2021;2:100176.","journal-title":"JTO Clin Res Rep"},{"key":"2901_CR16","doi-asserted-by":"publisher","first-page":"i57","DOI":"10.1093\/annonc\/mdv128.04","volume":"26","author":"J Spicer","year":"2015","unstructured":"Spicer J, Tischer B, Peters M. EGFR mutation testing and oncologist treatment choice in advanced nsclc: global trends and differences. Ann Oncol. 2015;26:i57.","journal-title":"Ann Oncol"},{"key":"2901_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.lungcan.2022.11.009","volume":"175","author":"J Subramanian","year":"2023","unstructured":"Subramanian J, Leighl NB, Choi YL, Chou TY, Gregg J, Hui R, et al. Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study. Lung Cancer. 2023;175:47\u201356.","journal-title":"Lung Cancer"},{"key":"2901_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejca.2022.05.012","volume":"171","author":"W Cui","year":"2022","unstructured":"Cui W, Milner-Watts C, O\u2019Sullivan H, Lyons H, Minchom A, Bhosle J, et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur J Cancer. 2022;171:44\u201354.","journal-title":"Eur J Cancer"},{"key":"2901_CR19","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1200\/JCO.2011.40.1315","volume":"30","author":"PA Janne","year":"2012","unstructured":"Janne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol. 2012;30:2063\u20139.","journal-title":"J Clin Oncol"},{"key":"2901_CR20","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","volume":"16","author":"C Rolfo","year":"2021","unstructured":"Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, et al. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021;16:1647\u201362.","journal-title":"J Thorac Oncol"},{"key":"2901_CR21","volume":"3","author":"JC Thompson","year":"2022","unstructured":"Thompson JC, Aggarwal C, Wong J, Nimgaonkar V, Hwang WT, Andronov M, et al. Plasma genotyping at the time of diagnostic tissue biopsy decreases time-to-treatment in patients with advanced NSCLC-results from a prospective pilot study. JTO Clin Res Rep. 2022;3:100301.","journal-title":"JTO Clin Res Rep"},{"key":"2901_CR22","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","volume":"25","author":"NB Leighl","year":"2019","unstructured":"Leighl NB, Page RD, Raymond VM, Daniel DB, Divers SG, Reckamp KL, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25:4691\u20134700.","journal-title":"Clin Cancer Res"},{"key":"2901_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107543","volume":"191","author":"L Gabriel","year":"2024","unstructured":"Gabriel L, McVeigh T, Macmahon S, Avila Z, Donovan L, Hunt I, et al. Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H family. Lung Cancer. 2024;191:107543.","journal-title":"Lung Cancer"},{"key":"2901_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101580","volume":"8","author":"EB Garon","year":"2023","unstructured":"Garon EB, Reck M, Nishio K, Heymach JV, Nishio M, Novello S, et al. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results. ESMO Open. 2023;8:101580.","journal-title":"ESMO Open"},{"key":"2901_CR25","doi-asserted-by":"crossref","unstructured":"Gray JE, Ahn MJ, Oxnard GR, Shepherd FA, Imamura F, Cheng Y, et al. Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA. Clin Cancer Res 2023.","DOI":"10.1158\/1078-0432.c.6752094.v2"},{"key":"2901_CR26","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.1158\/1078-0432.CCR-22-0741","volume":"28","author":"PC Mack","year":"2022","unstructured":"Mack PC, Miao J, Redman MW, Moon J, Goldberg SB, Herbst RS, et al. Circulating tumor DNA kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403). Clin Cancer Res. 2022;28:3752\u201360.","journal-title":"Clin Cancer Res"},{"key":"2901_CR27","doi-asserted-by":"publisher","first-page":"9064","DOI":"10.1200\/JCO.2023.41.16_suppl.9064","volume":"41","author":"D Nguyen","year":"2023","unstructured":"Nguyen D, Shum E, Baik CS, Janne PA, Patel JD, Schenk EL, et al. Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions. J Clin Oncol. 2023;41:9064\u20139064.","journal-title":"J Clin Oncol"},{"key":"2901_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.lungcan.2019.04.006","volume":"133","author":"M Schuler","year":"2019","unstructured":"Schuler M, Paz-Ares L, Sequist LV, Hirsh V, Lee KH, Wu YL, et al. First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Lung Cancer. 2019;133:10\u201319.","journal-title":"Lung Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02901-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02901-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02901-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T13:57:07Z","timestamp":1738591027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02901-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2,24]]}},"alternative-id":["2901"],"URL":"https:\/\/doi.org\/10.1038\/s41416-024-02901-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"21 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: Prof Popat\u2019s has consulting \/advisory Role with Amgen, AstraZeneca (AZ), Bayer, Blueprint, Bristol Myers Squibb (BMS), Boehringer Ingelheim, Daiichi Sankyo, GlaxoSmithKline (GSK), Guardant Health, Incyte, Janssen, Lilly, Merck Serono, Merck Sharp & Dohme (MSD), Novartis, Roche, Takeda, Pfizer, Seattle Genetics, Turning Point Therapeutics & EQRx. He has received payment\/Honoraria from AstraZeneca, Bayer, Guardant Health, Janssen, Merck Serono, Roche & Takeda. He has provided expert testimony to Roche, Merck Serono. He has received meeting attendance support from Janssen & Roche. He has a leadership \/ fiduciary Role with the British Thoracic Oncology Group (BTOG), ALK Positive UK, Lung Cancer Europe, Ruth Strauss Foundation, Mesothelioma Applied Research Foundation & ETOP-IBCSG Partners Foundation Board. Dr Januszewski has received grant\/holds contracts with Gilead & Roche. He has received teaching payments from AZ, Johnson and Johnson, Roche, Pfizer, MSD & Bayer. He has received meeting attendance support from Johnson & Johnson Pharmaceuticals & Roche Pharmaceuticals. He has an advisory role with BMS, AZ, Pfizer & MSD. He has a leadership\/fiduciary role with BTOG. Dr Ahmad has received speaker payment from AZ. She has received payment for an advisory project from Roche and meeting attendance support from Takeda. Dr Shah has an advisory role with BI. He has received meeting attendance support from BI. He has a leadership \/ fiduciary role with BTOG & EGFR\u2009+\u2009UK. Dr Geldart has received honoraria from Merck and meeting attendance support from BMS. Prof Spicer has consulting compensation to author\u2019s employer from AZ, BMS, GSK & RS Oncology; Advisory Board fees. He has an advisory role with CHM Cancer Vaccines Expert Working Group & CHM Expert Advisory Group on Oncology & Haematology. He has a leadership \/fiduciary role with BTOG & Experimental Cancer Medicine Centres. He has stock\/stock Options with Avacta & Epsiolgen. He has received reimbursements for treatment of trial patients from Achilles, BergenBio, BMS, Gilead, IO Biotech, Iovance, MSD, Roche, RS Oncology, Starpharma & Trizell. Dr Roitt has limited prior shares with Inivata. Dr Mulatero has stocks with Inivata. All remaining authors had no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The TIMELY trial was approved by the Scotland A Research Ethics Committee. Written informed consent was obtained from all patients. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}